Capricor Therapeutics’ (CAPR) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report released on Thursday,Benzinga reports. The firm currently has a $30.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $12.86 on Thursday. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The stock’s 50-day moving average is $14.06 and its two-hundred day moving average is $14.62. The firm has a market cap of $584.74 million, a P/E ratio of -12.13 and a beta of 4.10.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. On average, equities analysts expect that Capricor Therapeutics will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently made changes to their positions in the business. Summit Investment Advisors Inc. increased its stake in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares during the period. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth about $68,000. AlphaQuest LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $78,000. Finally, New York State Common Retirement Fund grew its position in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after buying an additional 5,000 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.